GYNECOLOGIC EFFECTS OF TAMOXIFEN AND THE ASSOCIATION WITH ENDOMETRIAL CARCINOMA

被引:79
作者
ASSIKIS, VJ [1 ]
JORDAN, VC [1 ]
机构
[1] NORTHWESTERN UNIV,SCH MED,ROBERT H LURIE CANC CTR,CHICAGO,IL 60611
关键词
TAMOXIFEN; ENDOMETRIAL CANCER; UTERUS; CARCINOMA;
D O I
10.1016/0020-7292(95)02387-R
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Tamoxifen has been used as an adjuvant therapy for breast cancer for nearly two decades. The benefits of adjuvant tamoxifen therapy in prolonging disease-free and overall survival have been shown in randomized clinical trials. Despite this, some developing evidence suggests that tamoxifen causes a 2- to 3-fold increase in endometrial cancer. This paper reviews the reports of endometrial carcinoma in tamoxifen-treated patients. Two hundred fifty cases of endometrial carcinoma are reported, but only one case is identified in a premenopausal woman. When documented, 77% (n = 127) of the eases are good-grade (grade 1 or 2) and 80% (n = 125) are stage-I disease. Since the distribution of good grade (79%) and stage I (74%) from the Surveillance, Epidemiology and End Results (SEER) data are comparable, concerns about more aggressive or late-stage disease appear to be unwarranted. The modest increase in the incidence of early-stage, good-grade endometrial carcinoma described during tamoxifen therapy suggests that it would be unreasonable to institute an aggressive detection strategy of endometrial biopsies. This approach would only lead to further detection bias and would not be cost-effective. Physicians should ensure that patients do not have pre-existing endometrial cancer prior to adjuvant tamoxifen therapy for breast cancer and, furthermore, they should educate patients about signs and symptoms of early endometrial carcinoma and when reported these should be followed up with a gynecologic examination.
引用
收藏
页码:241 / 257
页数:17
相关论文
共 87 条
[11]   TAMOXIFEN AS A POSSIBLE CHEMOTHERAPEUTIC AGENT IN ENDOMETRIAL ADENOCARCINOMA [J].
BONTE, J ;
IDE, P ;
BILLIET, G ;
WYNANTS, P .
GYNECOLOGIC ONCOLOGY, 1981, 11 (02) :140-161
[12]   ANTIESTROGENS AS TREATMENT OF FEMALE AND MALE INFERTILITIES [J].
BUVAT, J ;
BUVATHERBAUT, M ;
MARCOLIN, G ;
ARDAENSBOULIER, K .
HORMONE RESEARCH, 1987, 28 (2-4) :219-229
[13]  
Capurro I, 1992, Rev Chil Obstet Ginecol, V57, P351
[14]  
CHYONGHUEY L, 1994, BRIT J OBSTET GYNAEC, V101, P547
[15]  
CIATTO S, 1994, LANCET, V343, P60
[16]   OVARIAN ENDOMETRIOID CARCINOMA AND ENDOMETRIOSIS DEVELOPING IN A POSTMENOPAUSAL BREAST-CANCER PATIENT DURING TAMOXIFEN THERAPY - A CASE-REPORT AND REVIEW OF THE LITERATURE [J].
COHEN, I ;
ALTARAS, MM ;
LEW, S ;
TEPPER, R ;
BEYTH, Y ;
BENBARUCH, G .
GYNECOLOGIC ONCOLOGY, 1994, 55 (03) :443-447
[17]   ENDOMETRIAL CHANGES WITH TAMOXIFEN - COMPARISON BETWEEN TAMOXIFEN-TREATED AND NONTREATED ASYMPTOMATIC, POSTMENOPAUSAL BREAST-CANCER PATIENTS [J].
COHEN, I ;
ROSEN, DJD ;
SHAPIRA, J ;
CORDOBA, M ;
GILBOA, S ;
ALTARAS, MM ;
YIGAEL, D ;
BEYTH, Y .
GYNECOLOGIC ONCOLOGY, 1994, 52 (02) :185-190
[18]  
CORLEY D, 1992, OBSTET GYNECOL, V79, P111
[19]   GOLDENHARS-SYNDROME ASSOCIATED WITH TAMOXIFEN GIVEN TO THE MOTHER DURING GESTATION [J].
CULLINS, SL ;
PRIDJIAN, G ;
SUTHERLAND, CM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24) :1905-1906
[20]  
DALLENBACHHELLW.G, 1995, INT J GYNECOL PATHOL, V14, P7